Navigation Links
Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Date:9/5/2007

tion in TWT produced by EVT 201 was statistically significant for all hours of the night apart from hour 7 which came very close to reaching statistical significance (p= 0.058).

Commenting on the results, Dr John Kemp, Chief Research & Development Officer, Evotec AG, said: "I'm absolutely delighted with the results of this proof-of-concept Phase II study. The magnitude of effect on sleep maintenance appears more robust than those seen with other agents in similar cross-over design studies. In particular, we are not aware of similar studies that have demonstrated such statistically significant effects on Total Wake Time in the second half of the night and Total Wake Time each hour."

Jorn Aldag, President and Chief Executive Officer, Evotec AG, said: "Although certain aspects of insomnia are addressed by current treatments, there is no drug yet available which meets all the needs of insomnia patients. In our study EVT 201 demonstrated extremely robust findings on all key aspects of the problems faced by insomniacs, i.e. sleep onset and sleep maintenance and yet was without the patients feeling any drug hang-over effects after waking in the morning. We believe this gives EVT 201 a very competitive profile compared to the currently available insomnia treatments and to those in late stage clinical development."

Principal Investigator Dr James Walsh, Executive Director of the Sleep Medicine and Research Center, St John's Mercy Medical Center, Chesterfield, Missouri, US, said: "Due to its partial positive allosteric modulation of GABAA receptors, EVT 201 provides a novel approach to the treatment of insomnia, yet since the GABAA system is a well understood pathway, the risk of unexpected side effect findings are low compared to completely novel mechanisms. This together with robust effect sizes seen in this study, particularly with regard to sleep maintenance, offers considerable promise for the drug as a treatment for insomnia patients."

A second P
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 22, 2013 ... drug-only formulation of glycopyrronium bromide designed using Prosonix, particle ... company developing a portfolio of inhaled Respiratory Medicines ... study with PSX1002 that will assess its effect on ... doses in patients with moderate to severe chronic obstructive ...
(Date:5/21/2013)... new study led by George Washington University Professor ... of ice in small droplets is strongly size-dependent, ... the nanoscale. The formation of ice at the ... whose answer also has important implications for climate ... of ice from supercooled water is generally initiated ...
(Date:5/21/2013)... May 21, 2013 Smarter Security, Inc., ... solutions, today announced that Genzyme, a Sanofi company and ... Door Detective® CL for a multi-use facility in the ... four other Genzyme buildings, this latest order underscores the ... tailgate detection device improving doorway access control. ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... BURLINGAME, Calif., March 11, 2011 Apexigen, Inc., an ... antibody therapeutics, announced today that its partner, Simcere Pharmaceutical ... company in China, filed an Investigational New Drug (IND) ... of China to evaluate APX003 (also known as BD0801) ...
... consumer products continue to grow at a consistent ... Emerging Nanotechnologies (PEN) over 1,300 manufacturer-identified, nanotechnology-enabled products ... The most recent update to the group,s five-year-old ... particles in everything from conventional products like non-stick ...
... Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology ... December 31, 2010. The financial information contained in this ... financial statements, footnotes and independent auditors, report which have ... www.otcmarkets.com and on Dyadic,s website at www.dyadic.com ...
Cached Biology Technology:Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND 2Dyadic International Reports 2010 Fiscal Year Financial Results 2Dyadic International Reports 2010 Fiscal Year Financial Results 3Dyadic International Reports 2010 Fiscal Year Financial Results 4Dyadic International Reports 2010 Fiscal Year Financial Results 5Dyadic International Reports 2010 Fiscal Year Financial Results 6
(Date:5/21/2013)... new method for delivering molecules into single, targeted ... The technique could find applications in drug delivery, ... electroporation a technique used to deliver molecules ... membrane that are caused by exposing them to ... of cell transfection. (Cell transfection is the introduction ...
(Date:5/21/2013)... in pharmacies and health stores, phosphatidylserine is a ... soy. Proven to improve cognition and slow memory ... experiencing memory impairment. Now a team headed by ... Tel Aviv University,s Department of Human Molecular ... improves the functioning of genes involved in degenerative ...
(Date:5/21/2013)... Society (ACS), the world,s largest scientific society, invites ... & Exposition, September 8-12, 2013, in Indianapolis, Ind. ... Center and at area hotels. , With more ... science,s horizons from astronomy to zoology ― ... journalists a rich assortment of spot news and ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Common food supplement fights degenerative brain disorders 2
... 2010 In any battle, sizing up one,s opponent ... bacterial infection, that means assessing every nook and cranny ... attack. At the Center for Biological Research of ... maneuvers they hope will take out bacteria at their ...
... as the Most Innovative Company of the Year in Europe ... LIVINGSTON, ... ), developer of advanced upper-limb bionic technologies and clinical solutions, today ... Company of the Year in Europe in the 2010 ...
... Elsevier, a world-leading publisher of scientific, ... announced that Collexis, an Elsevier business and leading ... has launched its community module for their Expert ... Profiling connects experts across the Collexis community from ...
Cached Biology News:In the ring: Researchers fighting bacterial infections zero in on microorganism's soft spots 2In the ring: Researchers fighting bacterial infections zero in on microorganism's soft spots 3Touch Bionics announced as a winner in the Seventh Annual International Business Awards 2Touch Bionics announced as a winner in the Seventh Annual International Business Awards 3Collexis launches community feature for academic customers 2
... produces output at 470 nm; includes interface cable ... or installed into rack or desktop boxes ... is an LED that produces either pulsed or ... region -- for fluorescence measurements. The source is ...
Sterile, Cell culture tested...
With sodium bicarbonate. Sterile, Cell culture tested...
... Cost effective - Utilizes hands-off homogenization through a ... No grinding - Extract DNA without hand grinding; ... samples , Robust tubes - Includes ... without tube breakage , Flexible format ...
Biology Products: